Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

DSpace Repository

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

Author: Lieverse, Relinde I. Y.; Van Limbergen, Evert J.; Oberije, Cary J. G.; Troost, Esther G. C.; Hadrup, Sine R.; Dingemans, Anne-Marie C.; Hendriks, Lizza E. L.; Eckert, Franziska; Hiley, Crispin; Dooms, Christophe; Lievens, Yolande; de Jong, Monique C.; Bussink, Johan; Geets, Xavier; Valentini, Vincenzo; Elia, Giuliano; Neri, Dario; Billiet, Charlotte; Abdollahi, Amir; Pasquier, David; Boisselier, Pierre; Yaromina, Ala; De Ruysscher, Dirk; Dubois, Ludwig J.; Lambin, Philippe
Tübinger Autor(en):
Eckert, Franziska
Published in: Bmc Cancer (2020), Bd. 20, H. 1
Verlagsangabe: Bmc
Language: English
Full text: http://dx.doi.org/10.1186/s12885-020-07055-1
ISSN: 1471-2407
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)